康莱特注射液控制癌痛及提高晚期癌症患者生存质量Ⅲ期临床研究  

Clinical Study of Kanglaite Injection in Cancer Pain Control and Life Quality Improvement in Patients with Advanced Cancer

作　　者：李同度[1] 刘爱国[1] 秦叔逵 许佩珉 张文范 陈黎 程广源[1] 庄建生 张映红 刘炳奎 

机构地区：[1]安徽省肿瘤医院

出　　处：《中国肿瘤临床》1999年第5期372-376,共5页Chinese Journal of Clinical Oncology

摘　　要：目的：研究双相广谱抗癌新药康莱特注射液缓解癌痛及提高晚期癌症患者生存质量的作用。方法：本课题采用多中心协作，汇集我国１４家肿瘤医院３７６例晚期癌症患者临床治疗资料，其中伴有癌症疼痛患者３２８例，占８７２３％（３２８／３７６）。每位患者给予康莱特１００ｍｌｉｖｑｄ×２０天，观察治疗前后疼痛缓解，生活质量改善、免疫功能变化及不良反应。结果：癌症疼痛控制总有效率达８０４９％（部分缓解５６１０％，完全缓解２４３９％），用药结束后疼痛缓解仍可维持１～７天以上，且无成瘾性。在３７６例晚期癌症患者中，经康莱特治疗后９０％以上的晚期患者生存质量可以提高，并有提高机体免疫功能及升高外周血象作用。对康莱特不良反应观察，发现其对心、肝、肾功能无明显损害，约２５％的患者伴有轻度静脉炎。结论：康莱特在控制癌痛中可部分或全部替代吗啡类止痛药物。Cancer pain management with pallative care of advanced cancer patients is one of the four priorities of the comprehensive WHO Cancer Control Programme This study was carried out by clinical observation to evaluate the effect of the new drug-Kanglaite injection The clinical observation of 376 cases of advanced cancer patients who received Kanglaite injection was completed on a multi-institutional cooperative basis in 14 cancer hospitals in China Of these patients, 328 had cancer pain Each patient received Kanglaite injection at the dose of 100ml daily iv for 20 days The degree of pain relief, improvement of QOL and changes of immunological function were observed before and after treatment The results indicated that the total cancer pain relief rate was 8049%(PR 5610%+CR 2439%) In some cases, Kanglaite injection partially or completely replaced morphine which had been given before study for pain Analgesic effect might persist for 17 days after withdrawal of Kanglaite No psychological dependence was not advanced cancer patients had their QOL improved as well as immunological function and peripheral blood picture elevated Approximately 25%of the patients developed phlebitis No cardiac, liver or renal function damage were seen90%of the 376

关 键 词：康莱特 癌痛 生活质量 治疗 

分 类 号：R730.5[医药卫生—肿瘤]